Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy

Benjamin A Derman, James H Essell, Michael A. Kolodziej, Lavi Kwiatkowsky, Geoffrey Calkins, Christina M Parrinello, Mustafa S Ascha

Blood (2024) 144 (Supplement 1): 5046.

https://doi.org/10.1182/blood-2024-206505

Published: 2024

Journal Articles

Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics

James H Essell, Benjamin A Derman, Michael A. Kolodziej, Lavi Kwiatkowsky, Geoffrey Calkins, Christina M Parrinello, Mustafa S Ascha

Blood (2024) 144 (Supplement 1): 3756.

https://doi.org/10.1182/blood-2024-204413

Published: 2024

Journal Articles

Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation

Benjamin A Derman, Tadeusz Kubicki, Jennifer H Cooperrider, Anna Pula, Ken Jiang, Mariel Coradin, Ravleen Virdi, Fionn McLoughlin, Luciano Di Stefano, Vincent Bonifay, Caroline Rougé Dubroc, Andrzej J Jakubowiak

Blood (2024) 144 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2024-203566

Published: 2024

Journal Articles

Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Bei Wang, Benjamin A Derman, Zhou Zhang, Krissana Kowitwanich, John F. Cursio, Daniel Appelbaum, Chuan He, Wei Zhang, Andrzej J Jakubowiak, Brian Chiu

Blood (2024) 144 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2024-204305

Published: 2024

Journal Articles

Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Tadeusz Kubicki, Kaina Millan, Anna Pula, Henry Raeder, Quinn Hauck, Manoj Bhagwat, Jude Barton, Eyitayo Awe, Soma Das, Daniela Del Gaudio, Sulin Wu, Frank Wen, Jennifer H Cooperrider, Benjamin A Derman, Andrzej J Jakubowiak, Michael W Drazer

Blood (2024) 144 (Supplement 1): 3335.

https://doi.org/10.1182/blood-2024-207445

Published: 2024

Journal Articles

Association between Brain-to-Vein Time and Disease Characteristics and Outcomes for Commercial CAR T-Cell Therapy in Multiple Myeloma

Tyra K Grischke, Benjamin A Derman, Andrzej J Jakubowiak, Jennifer H Cooperrider

Blood (2024) 144 (Supplement 1): 7857.

https://doi.org/10.1182/blood-2024-210949

Published: 2024

Journal Articles

Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple

Jennifer H Cooperrider, Diren Arda Arda Karaoglu, Tadeusz Kubicki, Ken Jiang, Ella Postich, Kathryn Kimi Shimamoto, Olivia Arnold, Aubrianna Ramsland, Anna Pula, Jommel Macaraeg, Andrzej J Jakubowiak, Benjamin A Derman, Caner Saygin

Blood (2024) 144 (Supplement 1): 253.

https://doi.org/10.1182/blood-2024-208256

Published: 2024

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman, Jennifer H Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Ajay Major, Theodore Karrison, Ken Jiang, Tadeusz Kubicki, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2023-185309

Published: 2023

Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

Blood (2022) 140 (Supplement 1): 1360–1362.

https://doi.org/10.1182/blood-2022-160038

Published: 2022

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Anand Ashwin Patel, MD, Joseph Heng, MD, Emily Dworkin, PharmD, Sarah Monick, MD, Benjamin A Derman, MD, Sandeep Gurbuxani, MBBS, PhD, Satyajit Kosuri, MD, Hongtao Liu, MD PhD, Michael Thirman, MD, Lucy A. Godley, Olatoyosi Odenike, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138967

Published: 2020

Journal Articles

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Jagoda Jasielec, MD, Jeff Zonder, MD, Benjamin A Derman, MD, Donna E. Reece, MD, Craig E. Cole, MD, Jesus G. Berdeja, MD, Brittany Wolfe, Sarah Major, Kathryn M. Tinari, Andrew Stefka, MS, Fabrizio Fazzi, Megan Whelan, Christine Gleason, Amanda McIver, Evangelia Andreatos, Bernadette M. Libao, Daniel Juergens, Kent Griffith, Andrzej Jakubowiak, MD PhD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-141029

Published: 2020

Journal Articles

Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race

Lucia D Notardonato, MD, Spencer S Langerman, PhD, Brian C.-H. Chiu, PhD, Benjamin A Derman, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141930

Published: 2020

Journal Articles

Disparities in Renal Recovery Between African Americans Vs. Non African Americans Following Initial Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Chart Review

Benjamin A Derman, MD, Sanjib Basu, PhD, Agne Paner, MD

Blood (2016) 128 (22): 5610.

https://doi.org/10.1182/blood.V128.22.5610.5610

Published: 2016

Journal Articles

Risk Factors, Diagnosis, Management, and Outcomes For Splanchnic Vein Thrombosis: A Retrospective Analysis

Benjamin A. Derman, MD, Hau C. Kwaan, M.D, F.R.C.P.

Blood (2013) 122 (21): 2372.

https://doi.org/10.1182/blood.V122.21.2372.2372

Published: 2013

NARROW

Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy

Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics

Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation

Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Association between Brain-to-Vein Time and Disease Characteristics and Outcomes for Commercial CAR T-Cell Therapy in Multiple Myeloma

Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race

Disparities in Renal Recovery Between African Americans Vs. Non African Americans Following Initial Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Chart Review

Risk Factors, Diagnosis, Management, and Outcomes For Splanchnic Vein Thrombosis: A Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only